Shares of Jubilant Life Sciences may remain active, as the company has received final approval for the generic version of Crestor tablets from the US Food and Drug Administration.
It has received ANDA approval for Rosuvastatin calcium tablets (5 mg, 10 mg, 20 mg, and 40 mg strengths), used for the treatment of disorders resulting from high lipid levels in blood. So far in 2016, it has received seven approvals from the USFDA.